LIXTE BIOTECHNOLOGY HOLDINGS, INC. — Form 8-K

Lixte Biotechnology Holdings (public market cap ~$2.0M) executed Amendment No. 1 to its merger agreement with NOMAD Transportable Power Systems on June 30, 2026. The amendment modifies treatment of fractional shares: instead of cash payments, fractional shares now round to the nearest whole share (0.5+ rounds up, <0.5 rounds down). Schedule I (stockholder allocations) was updated accordingly. Concurrently, Lixte issued 51,500 shares of Series D Non-Voting Convertible Preferred Stock at $1,000 liquidation value per share (51.5M in preferred stock value), convertible to common stock at 1:1,000 ratio after stockholder approval. Registration rights and support agreements were executed. The merger's economic scale remains unclear without disclosed deal consideration, but the preferred stock issuance alone represents ~2,575% of Lixte's ~$2.0M market cap.